We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AKL Research & Development (AKLRD) and Nordic Bioscience Clinical Development, announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA).
"In addition to the efficacy of Taltz for people with skin symptoms, we are pleased to share new data suggesting that Taltz, if approved, may provide an option for those with joint symptoms of PsA."
Marianne Brodmann, M.D., of the Medical University of Graz in Austria, presented the data today as a late-breaking trial at the Vascular Interventional Advances (VIVA 17) Annual Conference.